1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsGenetic Research and Therapy (in California) is sponsored by The Grant Portal (Foundation listed through aggregator). This opportunity supports mission-aligned projects and measurable outcomes.
Get alerted about grants like this
Get emailed when new opportunities from “The Grant Portal (Foundation listed through aggregator)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Apply for Funding | Alliance for Cancer Gene Therapy Groundbreaking Research Apply for Funding Apply for research funding. Alliance for Cancer Gene Therapy current Request for Applications. 2026 ACGT Investigator Award in Cell and Gene Therapy for SOLID TUMOR CANCERS Applications are now closed 5-15-2026.
Alliance for Cancer Gene Therapy, Inc. (ACGT) funds breakthrough research that is transforming cancer treatment through cell and gene therapy. This ACGT grant award is for those conducting translational cell and gene therapy research specifically in solid tumor cancers . Frequently Asked Questions What types of grants are awarded?
Historically, Alliance for Cancer Gene Therapy has awarded clinical translation grants of $250,000 to $500,000 over two to three years, inclusive of a maximum of 10% indirect costs. Funds may be used at the recipient’s discretion for salary, technical assistance, supplies, animals or capital equipment, but may not support staff not directly related to the project, such as secretaries or administrative assistants.
Purchase of equipment is not allowed in the final year of the grant. Applicants must hold an MD, PhD, or equivalent degree and must be tenure-track or tenured faculty. While we recognize that there may be other excellent researchers not on a tenure-track, or not at medical schools or research centers, this is an eligibility requirement for application.
The investigator must be conducting original research as an independent faculty member. There are no citizenship restrictions, but research supported by the award must be conducted at academic medical centers or research centers located in the United States or Canada. If you already have an active ACGT Investigator Award, you are not eligible to apply until 24 months following the grant agreement’s effective date.
If a grant award is under a subsequent no-cost extension, it is unlikely that a second award would be made until the extension is completed. What is the review process? Members of our distinguished Scientific Advisory Council oversee the review and recommendation process.
All Letters of Intent (LOIs) are assessed by at least two members of the Council or their approved reviewers. Applicants whose LOIs are deemed responsive to the Request for Applications (RFA) and our mission are invited to submit full applications that include: biosketch, budget, research plan (10-page max), literature citations, and letter of reference.
Final applications are then carefully reviewed by the Council, which makes recommendations for final approval. What is the institutional policy? Grant funds are disbursed following execution of a grant agreement between the grantee institution and Alliance for Cancer Gene Therapy.
Who signs the application? Applications need to be signed by an appropriate representative of the institution, such as the Signing Official for Assurances in the Grants and Contacts Department and/or in the Legal Department. May I apply from an institution outside the United States?
Alliance for Cancer Gene Therapy has no citizenship restrictions, but research supported by its grants must be conducted at medical schools and research centers located in the United States or in Canada. Are literature citations part of the 10-page research plan limit? No. In addition to the 10-page research plan, an additional four pages are allowed for literature citations.
Can I revise my application after submission? No. Applications may be submitted only once, so please carefully read the instructions that appear throughout the application pages. If changes become necessary BEFORE the application deadline, please call Altum Proposal Central customer service at (-800) 875-2562.
No changes can be made AFTER the application deadline. Can I get funding alerts by email? Yes, please join our mailing list to receive updates about upcoming Requests for Applications.
Please join our mailing list to receive updates about Requests for Applications. Learn More About the Program --> “We are grateful for risk-taking organizations like Alliance for Cancer Gene Therapy that are willing to fund new ideas. If you want to fund the future of medicine, this is where to put your money.
” Icahn School of Medicine at Mount Sinai
According to the current listing, eligibility includes: Organizations and individuals based in California who are engaged in Science, Technology Research & Development. Small businesses in California can also apply. Confirm the full requirements in the official notice before applying.
Genetic Research and Therapy (in California) is funded by The Grant Portal (Foundation listed through aggregator). Verify program details on the funder's official page before applying.
This opportunity targets applicants in California. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The DOJ Bureau of Justice Assistance FY2026 Project Safe Neighborhoods formula program anticipates $19 million with a $1 million award ceiling and a requirement that 30% of funds support gang task forces. With a Grants.gov deadline of August 20, 2026, here is how the formula pass-through actually works, why the U.S. Attorney and the state administering agency both matter, and how community-based partners get funded.
Read articleThe May 29 OMB rewrite of 2 CFR Part 200 quietly rebuilds the pass-through entity compliance architecture. Proposed §200.332 strengthens subrecipient risk assessment, monitoring documentation, and remediation triggers. A new requirement mandates that every subaward be reported to SAM.gov with the reported records confirmed in performance reports — converting subaward administration from a back-office accounting function into a public-record certification regime. For the universities, state agencies, and national nonprofits that pass through more than half of their federal awards as subawards, the operational implication is a new compliance operating model that needs to be standing up by the October 1 effective date.
Read articleBuried in the May 29 OMB rewrite of 2 CFR Part 200 is the elimination of fixed-amount awards as a default grant instrument. Cost-reimbursement reverts to the standard. Here is what the change costs community-based nonprofits, pass-through subaward portfolios, SBIR Phase II direct-to-award structures, and the grant offices that have built workflows around milestone payments — and the comment-and-renegotiation strategy that has six weeks to land before July 13.
Read article